Given that KLF4/5 appeared to represent positively correlated prognostic factors in the HER2-enriched breast cancer subtype, we subsequently investigated the interdependence of KLF4/5 expression with exposure to, or resistance to, HER2-targeted therapy. The gene discussed is KLF4; the disease is breast carcinoma.